# Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Source: https://onco.cc/trials/nct04910022/  
OnCo record `nct04910022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Nerviano Medical Sciences, active and no longer recruiting.

## Summary

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma is a phase 1/2 interventional study registered as NCT04910022 by Nerviano Medical Sciences, with 150 participants enrolled, started 2021-12-01 and due to reach its primary completion in 2027-05-30. Interventions recorded: NMS-03305293 and Temozolomide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04910022
- Phase: 1/2
- Setting: A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma
- Sponsor: Nerviano Medical Sciences
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT04910022: https://clinicaltrials.gov/study/NCT04910022

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct04910022.json